BACKGROUND: Cardiac resynchronization therapy (CRT) is currently indicated in patients with moderate to severe heart failure, a wide QRS complex and significant left ventricular dysfunction despite optimal medical therapy. Adoption of these criteria for CRT results in a favorable response in only two thirds of candidates. METHODS: "Predictors of response to cardiac resynchronization therapy (PROSPECT)," a prospective, multicenter, nonrandomized study, aims to identify echocardiographic measures of dyssynchrony and evaluate their ability to predict response to CRT. PROSPECT will enroll approximately 300 patients in up to 75 centers in the United States, Asia, and Europe with clinical follow-up for 6 months. We will prospectively and individually test a variety of conventional echocardiographic and tissue Doppler imaging parameters against measures of clinical response. The primary response criteria are improvement in the heart failure Clinical Composite Score and left ventricular reverse remodeling. Enrollment began in March 2004 and is expected to conclude early 2005.
BACKGROUND: Cardiac resynchronization therapy (CRT) is currently indicated in patients with moderate to severe heart failure, a wide QRS complex and significant left ventricular dysfunction despite optimal medical therapy. Adoption of these criteria for CRT results in a favorable response in only two thirds of candidates. METHODS: "Predictors of response to cardiac resynchronization therapy (PROSPECT)," a prospective, multicenter, nonrandomized study, aims to identify echocardiographic measures of dyssynchrony and evaluate their ability to predict response to CRT. PROSPECT will enroll approximately 300 patients in up to 75 centers in the United States, Asia, and Europe with clinical follow-up for 6 months. We will prospectively and individually test a variety of conventional echocardiographic and tissue Doppler imaging parameters against measures of clinical response. The primary response criteria are improvement in the heart failure Clinical Composite Score and left ventricular reverse remodeling. Enrollment began in March 2004 and is expected to conclude early 2005.
Authors: Michel Lalonde; David Birnie; Terrence D Ruddy; Robert A deKemp; Richard W Wassenaar Journal: J Nucl Cardiol Date: 2010-04-29 Impact factor: 5.952
Authors: A Di Molfetta; L Santini; G B Forleo; M Cesario; C Tota; M Sgueglia; D Sergi; G Ferrari; F Romeo Journal: Med Biol Eng Comput Date: 2010-07-09 Impact factor: 2.602
Authors: Gabe B Bleeker; Cheuk-Man Yu; Petros Nihoyannopoulos; Johan de Sutter; Nico Van de Veire; Eduard R Holman; Martin J Schalij; Ernst E van der Wall; Jeroen J Bax Journal: Heart Date: 2007-11 Impact factor: 5.994